Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...
Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc.
US mRNA specialist Moderna today announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...
Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...
The Food and Drug Administration has approved Moderna's mNEXSPIKE (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least ...
“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said Stéphane Bancel, Chief Executive Officer of ...
Moderna (MRNA) announced preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, which targets the LP.8.1 variant of SARS-CoV-2 to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback